tbuckley/cabot-search huggingface dataset:
P3.14-017 Dosimetric Evaluation of Lung SBRT Treatment
Authors: P. Delgado, P. Carrasco, N. Farré, C. Cases, M. Lizondo, A. Latorre-Musoll, N. Jornet, T. Edualdo, A. Ruiz-Martinez, M. Majem, M. Ribas
Journal: Journal of Thoracic Oncology (2017)
Informe preliminar de una epidemia internacional de infecciones por Salmonella anatum asociadas a una leche maternizada, 1997
Authors: Royaume-Uni et le réseau Salm-Net
Journal: Eurosurveillance (1997)

El numero de aislamientos de Salmonella anatum en ninos (de 1 a 11 meses de edad) en Inglaterra y Gales fue superior al esperado en noviembre y diciembre de 1996 y principios de enero de 1997. El Laboratorio de Agentes Enteropatogenos (LEP) del 'Public Health Laboratory Service' (PHLS, Servicio de Laboratorios de Salud Publica) reconocio el aumento y a finales de enero de 1997 se inicio una investigacion. En un principio, entre el 'PHLS Communicable Disease Surveillance Centre' (CDSC, Centro para la Vigilancia de las Enfermedades Transmisibles) y el 'Scottish Centre for Infection y Environmental Health' (SCIEH, Centro Escoces para el Estudio de Infecciones y Salud Ambiental), se identificaron 12 casos de infeccion por S. anatum en ninos del Reino Unido (RU), ocho en Inglaterra y cuatro en Escocia. La edad de estos casos condujo las sospechas directamente a los alimentos para bebes como posible vehiculo. Se comprobo la base de datos internacional 'Salm-Net' de vigilancia de la salmonella y se pidio a los colaboradores de todos los paises europeos participantes, informacion relativa sobre casos recientes en sus respectivos paises.
MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients
Authors: H. Wakelee, R. Sanborn, J. Nieva, S. Waqar, C. Brzezniak, J. Bauman, J. Neal, G. Dukart, F. Tan, K. Harrow, C. Liang, L. Horn
Journal: Journal of Thoracic Oncology (2017)
NTOX-08. CYSTIC ENLARGEMENT DURING CHEMOTHERAPY AND GROWING TERATOMA SYNDROME IN NON-GERMINOMATOUS GERM CELL TUMOR
Authors: Fumiyuki Yamasaki, Takeshi Takayasu, Yasuyuki Kinoshita, Satoshi Usui, Motoki Takano, Manish Kolakshyapati, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2017)

The term “growing teratoma syndrome (GTS)” was used with an extended interpretation from original report by Logothetis et al. as patients with germ cell tumors who present with enlarging original/metastatic masses during or after appropriate systemic chemotherapy despite normalized serum markers. In other words, the definition of the term GTS is not fully established. In this study, we defined primary GTS (p-GTS) as the patients who developed cystic enlargement during treatment, and recurrent GTS (r-GTS) as the patients who developed enlargement of teratoma after CR of initial tumors as reported by Logothetis et al. We analyzed the risk of GTS in the patients with non-germinomatous GCT (NGGCT). Between 2003 and 2017, we treated 14 patients (14 male; age ranging 5.4 to 51.9, median 13.8) with NGGCT at our institution of which two were surgically removed before chemotherapy and were excluded. We reviewed the changes in imaging features in 12 patients with NGGCT during this treatment period. Among 12 patients, 1 patient achieved CR. In 11 non-CR patients, we surgically confirmed mature/immature teratoma component. Six of 11 patients showed p-GTS, and three showed enlargement of total tumor volume despite decrease in the volume of solid components. Among 3, only one patient completed the planned protocol of chemotherapy and radiotherapy. One was asymptomatic but had to stop chemotherapy, and the other developed hearing disturbance followed by altered consciousness resulting from compression of brainstem and underwent surgical removal after discontinuing radiochemotherapy. One patient developed r-GTS. Patients with the cyst less than 5mm did not develop the p-GTS. However, no imaging feature was predictive for GTS in our results. The incidence of p-GTS is not rare. Physicians need to be aware of this important phenomenon. Future study is necessary to confirm the etiology and predictive factor of GTS.
The ENDOPREDICT® molecular test for breast cancer prognosis: clinical-pathological correlations and therapeutic implications on a selected cohort of patients
Authors: I. Castellano, J. Metovic, D. Balmativola, P. Francia Di Celle, L. Riera, O. Bertetto, M. Mistrangelo, P. Cassoni, C. Marchiò, A. Sapino
Journal: Annals of Oncology (2017)
DDIS-22. ANTI-DEPRESSANT, SSRI IDENTIFIED BY DRUG REPOSITIONING SYSTEM, BLOCKED GLIOBLASTOMA INVASION WITH TARGETING TO INHIBIT ACTIN POLYMERIZATION
Authors: Hiroyuki Michiue, Keiichiro Hayashi, Atsushi Fujimura, Hiroaki Matsushita, Tei-ichi Nishiki, Hideki Matsui
Journal: Neuro-Oncology (2017)

Invasion of Glioblastoma (GBM) cells into normal brain is the major cause of poor prognosis and requires dynamic reorganization of the actin cytoskeleton, which includes lamellipodial protrusions, focal adhesions, and stress fibers at the leading edge of GBM cells. Therefore, we hypothesized that inhibitors of actin polymerization can suppress GBM migration and invasion. We adopted a drug repositioning system for screening with a pyrene-actin-based actin polymerization assay and identified fluvoxamine, a clinically used antidepressant. Fluvoxamine, selective serotonin reuptake inhibitor, was a potent inhibitor of actin polymerization and confirmed as drug penetration through the blood–brain barrier (BBB) and accumulation of whole brain including brain tumor with no drug toxicity. Fluvoxamine inhibited serum-induced ruffle formation, cell migration, and invasion of human GBM and glioma stem cells in vitro by suppressing FAK signaling. Fluvoxamine showed no drug toxicity. Daily treatment of athymic mice bearing human glioma-initiating cells with fluvoxamine blocked tumor cell invasion and prolonged the survival with almost same doze of anti-depressant effect. In conclusion, Fluvoxamine is a promising anti-invasive treatment against GBM with reliable approach. Key words, glioma, invasion, actin-polymerization, SSRI, Drug repositioning
HOUT-21. THE EFFECT OF POSTOPERATIVE INFECTION ON SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
Authors: Yi-Ren Chen, Jon Sole, Beatrice Ugiliweneza, Eric Burton, Shiao Woo, Maxwell Boakye, Stephen Skirboll
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is a primary glial neoplasm with a median survival of approximately one year. There are anecdotal reports that postoperative infection may confer a survival advantage in patients with GBM. However, only a few case reports in the literature, along with two retrospective cohort studies show some potential link between infection and prolonged survival in GBM patients. The objective of this study was to evaluate the effect of postoperative infection in patients with GBM using a large national database. The linked Surveillance, Epidemiology, and End Results (SEER) – Medicare database was searched to identify patients, 66 years and older with GBM with and without infection from 1997-2010. The primary outcome was survival after diagnosis. The statistical analysis was performed with a graphical representation by Kaplan Meier curves, a univariate analysis with the log-rank test and multivariate analysis with the proportional hazard modeling. 3,784 patients with GBM were identified from the database, and from these, 369 patients (9.8%) had postoperative infection. In GBM patients who had an infection within one-month of surgery, there was no difference in survival (5 months) compared to patients with no infection (6 months) (P=0.17). We also showed that older age, increased Gagne comorbidity score, and having diabetes may be negatively associated with survival. Infection after craniotomy within one-month was not associated with a survival benefit in patients with GBM.
MA 10.10 Tumor Draining Lymph Node Immunophenotype Corresponds with Primary Tumor Characteristics in Patients with Non-Small Cell Lung Cancer
Authors: V. Murthy, J. Tsay, J. Minehart, K. Mangalick, J. Bessich, G. Michaud, M. Curotto De Lafaille, K. Wong, C. Goparaju, H. Pass, D. Sterman
Journal: Journal of Thoracic Oncology (2017)
Abstract 14475: Echocardiographic Predictors of Long Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What is the Optimal Metric?
Authors: John Rickard, Richard Grimm, Zoran Popovich, Patrick Collier, Bryan Baranowski, Wilson Tang, Mark Niebauer, Bruce Wilkoff, Niraj Varma
Journal: Circulation (2016)

Background: The reverse ventricular remodeling (RVR) effects of cardiac resynchronization therapy (CRT) are used as descriptors of treatment effect and surrogates for outcomes. Multiple definitions...
P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor
Authors: M. Kris, D. Aisner, L. Sholl, L. Berry, M. Rossi, H. Chen, J. Fujimoto, A. Moreira, S. Ramalingam, L. Villaruz, G. Otterson, E. Haura, K. Politi, B. Glisson, J. Cetnar, E. Garon, J. Schiller, S. Waqar, L. Sequist, J. Brahmer, Y. Shyr, K. Kugler, I. Wistuba, B. Johnson, J. Minna, P. Bunn, D. Kwiatkowski
Journal: Journal of Thoracic Oncology (2017)
ATIM-22. ADOPTIVE IMMUNOTHERAPY USING LYMPHOKINE-ACTIVATED αβ T-CELLS IMPROVES TEMOZOLOMIDE-INDUCED LYMPHOPENIA IN PATIENTS WITH GLIOMA
Authors: Yonehiro Kanemura, Miho Sumida, Yoshiko Okita, Ema Yoshioka, Atsuyo Yamamoto, Daisuke Kanematsu, Yukako Handa, Hayato Fukusumi, Yui Nozaki, Ai Takada, Masahiro Nonaka, Shin Nakajima, Kanji Mori, Shigenori Goto, Takashi Kamigaki, Tomoko Shofuda, Shusuke Moriuchi, Mami Yamasaki
Journal: Neuro-Oncology (2017)

Primary and metastatic malignant brain tumors are intractable cancers for which there are limited treatment options and an extremely poor prognosis, and new therapeutic strategies need to be continuously developed. Many new approaches are currently being investigated for treating malignant brain tumors including glioblastoma multiforme (GBM), among which immunotherapy is very promising and attractive. In this clinical study, we investigated the safety and clinical usefulness of systemic adoptive immunotherapy using autologous lymphokine-activated αβ T-cells (αβ T-cells), combined with standard therapies, in patients with malignant brain tumors. Twenty-three patients with different malignant brain tumors, consisting of 14 treated with temozolomide (TMZ group) and nine treated without temozolomide (non-TMZ group), received systemic intravenous injections of αβ T-cells (mean=10.4 injections/patient for the TMZ group, and 4.78 for the non-TMZ group). No significant adverse effects associated with the αβ T-cell injection were observed, and the total lymphocyte count (TLC) improved significantly in the TMZ group after five injections. Furthermore, CD8-positive or T-cell receptor V gamma -positive cells were increased with TLC in three patients with GBM. These findings suggest that systemic αβ T-cell immunotherapy is well tolerated, and may help restore an impaired and imbalanced T-cell immune status, and temozolomide and/or radiotherapy-induced lymphopenia.
Focolaio epidemico di gastroenterite associata al consumo di lamponi surgelati
Authors: A Pönka, L Maunula, C. H. von Bonsdorff, O Lyytikaïnen
Journal: Eurosurveillance (1999)

I piccoli virus a struttura tondeggiante (Small Round Structured Viruses - SRSVs - ad esempio, i calici-, gli astro-, e gli enterovirus) rappresentano in tutto il mondo la causa piu comune dei focolai di gastroenterite non batterica (1,2). E' stata documentata la trasmissione degli SRSVs attraverso l'acqua e vari alimenti, incluse insalate, prodotti da forno, frutta fresca a pezzi, pollo, ostriche e cozze. Normalmente, eccetto nel caso di focolai associati all'acqua o ai molluschi, la contaminazione virale degli alimenti e stata attribuita a lavoratori infetti. Il recente sviluppo di metodi molecolari per scoprire ed identificare gli SRSVs ha aumentato la sensibilita e la specificita con cui e possibile diagnosticare le gastroenteriti virali (3, 4).
P3.15-012 Surgical Outcome in Early Stage Small Cell Lung Cancer
Authors: K. Inafuku, H. Ito, H. Nakayama, T. Nagashima, J. Samejima, J. Osawa, M. Nito, K. Yamada, T. Yokose, M. Masuda
Journal: Journal of Thoracic Oncology (2017)
L’éradication de la coqueluche : un défi en santé publique
Authors: S Salmaso
Journal: Eurosurveillance (1999)

La coqueluche et la vaccination anti-coquelucheuse, en particulier les essais cliniques menes quasi-simultanement par differents pays europeens, ont fait l’objet d’un vif debat au cours des dix dernieres annees. Plusieurs points importants en sante publique restent cependant a eclaircir. Les trois articles publies dans ce numero d’Eurosurveillance constituent de bons exemples des situations auxquelles differents pays europeens ont ete confrontes. Les lecons suivantes peuvent en etre tirees : l’introduction de la vaccination diminue l’incidence (comme le montre l’experience suedoise) ; l’evaluation de l’incidence de la coqueluche peut etre difficile en cas de changements introduits dans le systeme de surveillance (en Suisse, la PCR (polymerase chain reaction) a ete ajoutee pour ameliorer la specificite du diagnostic et les Pays-Bas ont ajoute des criteres serologiques) ; et enfin des epidemies peuvent survenir en depit d’une couverture vaccinale maintenue elevee (comme aux Pays-Bas).
The Need for Better Data Breach Statistics
Authors: Daniel Fabbri, Mark E. Frisse, Bradley Malin
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
MA 01.02 Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers Versus Heavy Smokers
Authors: A. Cardona, O. Arrieta, L. Rojas, Z. Zatarain-Barron, L. Corrales, C. Martin, J. Rodriguez, J. Rodriguez, P. Archila, A. Ruiz-Patiño, R. Rosell
Journal: Journal of Thoracic Oncology (2017)
Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer
Authors: Ami Vyas, S. Suresh Madhavan, Usha Sambamoorthi, Xiaoyun (Lucy) Pan, Michael Regier, Hannah Hazard, Sita Kalidindi
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: Understanding the patterns of healthcare utilization and costs during the initial phase of care (12 months after breast cancer [BC] diagnosis) in older women (aged ≥65 years) is crucial in the allocation of Medicare resources. The objective of this study was to determine healthcare utilization and costs during the initial phase of care in older, female, Medicare fee-for-service beneficiaries diagnosed with BC, and to determine the factors associated with higher costs. Methods: A retrospective observational study using the SEER-Medicare linked database was conducted in 69,307 women aged ≥66 years diagnosed with primary incident BC in 2003–2009 to determine healthcare utilization, average costs, and costs for specific services during the initial phase of care. Generalized linear model regression was conducted to identify the factors associated with higher costs in a multivariate framework. Results: A total of 96% of women were treated with surgery during the initial phase of BC care, whereas 21% and 54% underwent chemotherapy and radiotherapy, respectively. Costs during the initial phase of care totalled $28,075 in 2012 USD, comprising $13,344 for physician services and $7,456 for outpatient services. Factors associated with higher costs during the initial phase of care were younger age (66–69 years), African American race, higher household income, advanced stages of BC, initial BC treatment, higher number of primary care physician visits, and presence of comorbidities and/or a mental condition. Conclusions: The economic burden of BC is substantial during the initial phase of care. Physician and outpatient services accounted for the highest proportion of costs. Predisposing factors, need-related factors, healthcare use, and external environmental healthcare factors significantly predicted costs during the initial phase of care.
DDIS-14. THE EFFECT OF BETULINIC ACID ON TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
Authors: Wei-Lun Lo, Yung-Ning Huang, Tsung-I Hsu, Jian-Ying Chuang
Journal: Neuro-Oncology (2017)

Glioblastoma multiform (GBM) is the most fatal cancer of all brain cancers, and the standard care protocol of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ)-mediated chemotherapy. However, tumor recurrence always occurs, and recurrent GBM exhibits more malignant and less sensitivity in response to chemotherapy. Therefore, to develop a new therapeutic strategy is urgent needed. Betulinic acid (BA) is a plant-derived pentacyclic triterpenoid showing cytotoxicity towards a variety of cancer types, but not to normal cells and tissues. Additionally, previous studies have shown that BA penetrates blood-brain-barrier with a high efficiency which is not achieved by most anti-tumor compounds. Thus we studied the effect of BA on TMZ-resistant GBM and its mechanism of the anti-cancer actions. Here, we found that (1) Sp1 transcription factor was highly express in TMZ-resistant GBM cells, (2) BA treatment inhibited Sp1 expression, (3) BA caused viability decreased in GBM cells and TMZ-resistant GBM cells, (4) BA induced apoptosis in GBM cells and TMZ-resistant GBM cells. In conclusion, our results suggest that Sp1 as a critical factor modulates the resistance of GBM to an antitumor drug, but BA can inhibit the survival of TMZ-resistant GBM cells by affecting the activity of Sp1 transcription factor. In addition, targeting Sp1 by BA may be a good therapeutic strategy for preventing brain tumor resistance to chemotherapy.
SCDT-19. DELIVERY OF ISPINESIB IS LIMITED BY EFFLUX TRANSPORT AT THE BLOOD-BRAIN BARRIER (BBB)
Authors: Gautham Gampa, James Crish, Karen Parrish, Nicholas Cook-Rostie, Minjee Kim, Janice Laramy, Steven Rosenfeld, William Elmquist
Journal: Neuro-Oncology (2017)

A challenge in developing therapies for GBM is the inability of drugs to cross the BBB. Ispinesib, an inhibitor of kinesin spindle protein, has potent anti-cancer activity by causing mitotic arrest and growth inhibition. The objective was to determine the distribution of ispinesib across the BBB, and determine mechanisms responsible for limiting brain delivery. Brain distribution studies were conducted in FVB wild-type (WT), triple-knockout (TKO; Mdr1a/b(-/-)Bcrp1(-/-)), P-gp knockout (PKO; Mdr1a/b(-/-)) and Bcrp knockout (BKO; Bcrp1(-/-)) mice. In a separate study, WT mice administered with and without elacridar (n=5) were co-dosed ispinesib. Plasma and brain were collected one-hour post dose. Brain distribution studies were conducted in WT and TKO mice, and plasma and brain were harvested at 7 time points. Rapid equilibrium dialysis assessed the unbound fractions of ispinesib in plasma and brain. All the samples were analyzed using LC-MS/MS. The single time point studies show that the brain concentrations in WT and BKO mice are significantly lower than in plasma, and brain-to-plasma ratios (B:P) in WT and BKO mice were below 2%. Brain concentrations in TKO and PKO mice are significantly higher than WT and BKO. The B:P was increased in the TKO and PKO mice [(WT: 0.0071 ± 0.01; BKO: 0.016 ± 0.01 (not significant); TKO: 0.35 ± 0.25 (p=0.0140); PKO: 0.54 ± 0.14 (p=0.0005)]. Plasma concentrations in WT and TKO mice following oral administration of ispinesib were about 33% of plasma concentrations following i.p. dosing and the B:P ratios were similar. Brain concentrations are less than 5% of plasma following elacridar co-administration, and did not cause a significant increase in ispinesib brain delivery. Brain delivery of ispinesib is restricted by active efflux transporters (P-gp). The pharmacokinetic studies in FVB mice post intravenous administration will confirm the findings from single time point studies.
Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series
Authors: E. Di Liso, A. Pavan, M. Schiavon, D. Gregori, G. Comacchio, I. Attili, M. Mantiero, G. Pasello, G. Zago, V. Polo, S. Frega, N. Milite, F. Rea, P. Conte, L. Bonanno
Journal: Annals of Oncology (2017)
P1.02-061 Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Unfavorable Prognosis in Patients with Stage IA Adenocarcinoma
Authors: Y. Kubouchi, W. Fujiwara, Y. Kidokoro, T. Ohno, Y. Yurugi, M. Wakahara, Y. Takagi, K. Miwa, K. Araki, Y. Taniguchi, H. Nakamura, Y. Umekita
Journal: Journal of Thoracic Oncology (2017)
Surto de polio na Albânia, 1996
Authors: M L Ciofi Degli Atti, R Prevots, A Sallabanda, P Malfait, E Diamantil, B Aylward, D Greco, S Wassilak
Journal: Eurosurveillance (1997)

Entre Abril e Novembro de 1996, ocorreu um grande surto de polio na Albânia, pais tido como livre da doenca desde 1985. Embora a Albânia nao tenha notificado casos de polio, durante este periodo, o risco da introducao e circulacao de poliovirus selvagem aumentou. Este risco resultou de problemas na manutencao da cadeia do frio dos fornecimentos da vacina no passado, da diminuicao da cobertura com a vacina antipolio oral (VOP), ocorrida no inicio de 1990 durante a transicao politica e da abertura das fronteiras que provocou uma migracao massiva desde 1992, da qual resultou um contacto facilitado com populacoes de paises onde a polio e endemica. Para controlar este risco, foram levados a cabo, durante os meses de Abril e Maio de 1996, por toda a Albânia, Dias Nacionais de Vacinacao contra a Polio (DNVs), dirigida a populacao infantil ate aos 5 anos de idade, tendo-se conseguido uma cobertura vacinal de 98%.
Reply
Authors: Bryant R. England, Ted R. Mikuls, Jeffrey R. Curtis
Journal: Arthritis & Rheumatology (2017)

We thank Dr. Bigler and his colleagues for their interest in our article and sharing the results from their laboratory. The authors proposed evaluating a biologic mechanism linking Varicella Zoster Virus (VZV) to giant cell arteritis (GCA) through assessment of cross-reactive VZV-specific T cell immunity, hypothesizing that VZV reactive T-cells would be increased in GCA patients relative to controls. However, their in vitro results from a small sample of GCA and control (inflammatory and non-inflammatory) patients designed to test this hypothesis through the quantification of VZV specific T-cells and T-cell reactivity (in response to stimulation with a protein extract from an aortic specimen of a single GCA patient) found no significant differences between cases and controls.

This article is protected by copyright. All rights reserved.